Takeda Pharmaceutical (NYSE:TAK) Posts Earnings Results, Beats Expectations By $0.36 EPS

Takeda Pharmaceutical (NYSE:TAK) released its quarterly earnings results on Wednesday. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.36, Zacks reports. The company had revenue of $28.19 billion for the quarter, compared to analysts’ expectations of $7.14 billion. Takeda Pharmaceutical had a return on equity of 11.23% and a net margin of 4.31%. Takeda Pharmaceutical updated its FY 2026 guidance to 3.009-3.009 EPS.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Takeda said fiscal 2025 was a strong year for its pipeline, with positive Phase III data for oveporexton, rusfertide and zasocitinib, plus positive pivotal results for TAK-881. Management framed these as setting up multiple near-term launches and a broader late-stage pipeline with significant long-term potential.
• FY2025 core revenue was about JPY 4.5 trillion and core operating profit was JPY 1.17 trillion, with results pressured by Vyvanse generic erosion but supported by disciplined cost control. Core EPS still grew 3.1% at constant currency, and free cash flow remained strong at JPY 684.5 billion.
• The company highlighted three major launches expected within the next 12 months: oveporexton for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. Takeda said all three have priority review status or equivalent momentum and could become future blockbuster brands.
• FY2026 guidance calls for low-single-digit revenue decline and core operating profit down 5% to 8% at constant exchange rates, as Takeda invests heavily in launches and R&D. The company also expects about JPY 170 billion of restructuring costs and roughly 4,500 roles impacted by its transformation program.
• Management said its new transformation program should deliver more than JPY 200 billion of annualized gross savings by FY2028, supporting a return to growth and helping fund future launches. Takeda also plans to increase the annual dividend to JPY 204 per share and continue deleveraging toward a 2x net debt/EBITDA target.

Takeda Pharmaceutical Price Performance

NYSE:TAK traded down $0.02 during midday trading on Friday, hitting $16.61. 2,789,063 shares of the stock were exchanged, compared to its average volume of 3,043,384. Takeda Pharmaceutical has a one year low of $12.99 and a one year high of $18.90. The company has a market capitalization of $52.86 billion, a price-to-earnings ratio of 42.59 and a beta of -0.06. The business has a 50-day moving average price of $17.62 and a two-hundred day moving average price of $16.41. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TAK. Compound Planning Inc. grew its position in Takeda Pharmaceutical by 8.3% in the fourth quarter. Compound Planning Inc. now owns 45,673 shares of the company’s stock worth $712,000 after buying an additional 3,515 shares during the last quarter. Summit Global Investments grew its position in Takeda Pharmaceutical by 22.5% in the fourth quarter. Summit Global Investments now owns 104,373 shares of the company’s stock worth $1,627,000 after buying an additional 19,171 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in Takeda Pharmaceutical in the fourth quarter worth approximately $360,000. XTX Topco Ltd grew its position in Takeda Pharmaceutical by 437.7% in the fourth quarter. XTX Topco Ltd now owns 71,476 shares of the company’s stock worth $1,114,000 after buying an additional 58,183 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its position in Takeda Pharmaceutical by 1,070.7% in the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after buying an additional 880,289 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TAK. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a report on Wednesday, April 29th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Wall Street Zen raised Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 11th. Finally, Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.